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Recently, the National Surgical Adjuvant Study of Colorectal Cancer in Japan, a randomised controlled trial of oral uracil–tegafur
(UFT) adjuvant therapy for stage III rectal cancer, showed remarkable survival gains, compared with surgery alone. To evaluate value
for money of adjuvant UFT therapy, cost-effective analysis was carried out. Cost-effectiveness analysis of adjuvant UFT therapy was
carried out from a payer’s perspective, compared with surgery alone. Overall survival and relapse-free survival were estimated by
Kaplan–Meier method, up to 5.6 years from randomisation. Costs were estimated from trial data during observation. Quality-
adjusted life-years (QALYs) were calculated using utility score from literature. Beyond observation period, they were simulated by the
Boag model combined with the competing risk model. For 5.6-year observation, 10-year follow-up and over lifetime, adjuvant UFT
therapy gained 0.50, 0.96 and 2.28 QALYs, and reduced costs by $2457, $1771 and $1843 per person compared with surgery alone,
respectively (3% discount rate for both effect and costs). Cost-effectiveness acceptability and net monetary benefit analyses showed
the robustness of these results. Economic evaluation of adjuvant UFT therapy showed that this therapy is cost saving and can be
considered as a cost-effective treatment universally accepted for wide use in Japan.
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Colorectal cancer is a major health problem worldwide (Beretta
et al, 2004; Bernold and Sinicrope, 2006; Monga and O’Connell,
2006). It is the second most frequent cause of cancer death in the
United States and most European countries. In Japan, although its
number of deaths ranks third, the disease incidence has recently
been increasing (Committee of Cancer Statistics, 2005; Ministry of
Health, Labor and Welfare, 2006). The prognosis of patients with
colorectal cancer has improved steadily over the past several
decades, owing to the development of effective therapies
(Ragnhammar et al, 2001; Beretta et al, 2004; Bernold and
Sinicrope, 2006; Monga and O’Connell, 2006). In practice, surgery
remains the primary treatment modality for localised colorectal
cancer. Adjuvant therapy is given in an attempt to eradicate
micrometastases and to thereby increase the cure rate after
surgical resection.
The natural history of rectal cancer differs from that of colon
cancer for epidemiological, anatomical and pathophysiological
reasons (Beretta et al, 2004; Bernold and Sinicrope, 2006;
Monga and O’Connell, 2006). In the adjuvant therapy for stage
III rectal cancer, a combined modality therapy consisting of i.v.
5-fluorouracil (5-FU) and radiotherapy is the standard care
(Beretta et al, 2004; Bernold and Sinicrope, 2006; Monga and
O’Connell, 2006). However, the use of chemotherapy has been
based on the evidence of postoperative adjuvant chemotherapy
in colon cancer, not rectal cancer (Takiuchi, 2006). In rectal
cancer, there is only one adjuvant therapy (i.e., the MOF in
the NSABP R-01 study), which showed improvement of
overall survival (OS) and disease-free survival (DFS), compared
with surgery alone as the control (Fisher et al, 1988). The optimal
timing of adjuvant therapy and the combination of agents continue
to evolve. As with in colon cancer (Andre ´ et al, 2004; Twelves
et al, 2005; Bernold and Sinicrope, 2006; Lembersky et al, 2006;
Monga and O’Connell, 2006), trials of the combinations of
several active drugs, such as oral fluoropyrimidines (i.e., uracil–
tegafur (UFT) and capecitabine), oxaliplatin and irinotecan,
are under way (Bernold and Sinicrope, 2006; Monga and
O’Connell, 2006).
As to radiotherapy, a meta-analysis confirmed that post-
operative adjuvant radiotherapy significantly reduced local recur-
rence, but not overall and cancer-specific mortality (Colorectal
Cancer Collaborative Group, 2001). In contrast, meta-analyses
have shown that preoperative radiotherapy reduces local recur-
rence, and overall and/or cancer-specific mortality (Camma ` et al,
2000). However, randomised controlled trials (RCTs) included in
these meta-analyses all started before the broad introduction of
total mesorectal excision (TME). The RCT of TME with or without
preoperative radiotherapy showed that there was no difference in
OS and DFS, except for local recurrence (Kapiteijn et al, 2001).
Preoperative chemoradiotherapy, as compared with postoperative
chemoradiotherapy, decreased local recurrence, but improved
neither OS nor DFS (Sauer et al, 2004). Moreover, preoperative
short-term radiotherapy was suggested to cause delayed adverse
reactions (Peeters et al, 2005). Therefore, preoperative adjuvant
radiotherapy or chemoradiotherapy for rectal cancer should also
be carefully evaluated.
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sIn Japan, in contrast to Europe and the United States above,
postoperative adjuvant chemotherapy using oral fluoropyrimidines
such as UFT, without radiation, has been the primary treatment,
mainly because of excellent outcomes of TME with lateral pelvic
lymphadenectomy (Takiuchi, 2006). The local recurrence rate in
this extended TME was estimated to be lower than simple TME
(Akasu and Moriya, 1997; Mori et al, 1998). Although individual
RCTs comparing oral fluoropyrimidines with surgery alone showed
improvement in both DFS and local recurrence in rectal cancer, but
not in OS (Kodaira et al, 1998; Kato et al, 2002), meta-analyses of
RCTs related to fluoropyrimidines in the 1980s showed significant
benefits in both DFS and OS (Sakamoto et al, 1999; Meta-Analysis
Group, 2004). In contrast, there has been no evaluation on DFS and
OS in other therapies including 5-FU/leucovorin (LV) and radiation,
in Japan. On the basis of the evidence, UFT is indicated as the
first-line treatment of adjuvant chemotherapy after surgery for
stage III rectal cancer in Japan (Japan Society for Cancer of the
Colon and Rectum, 2005).
Recently, the National Surgical Adjuvant Study of Colorectal
Cancer (NSAS-CC) in Japan (Akasu et al, 2006), an RCT of UFT
adjuvant therapy for stage III rectal cancer, showed remarkable OS
and RFS gains, compared with surgery alone. These results may be
attributed to a higher dosage of UFT, rigorous surgical procedures
and high quality of the clinical trial. The dosage of UFT per day of
600mg in this study was greater than the 300–400mg used in
previous UFT studies (Kodaira et al, 1998; Sakamoto et al,1 9 9 9 ;K a t o
et al, 2002; Meta-Analysis Group, 2004). In this study, TME with
lateral pelvic lymphadenectomy was chosen as the control treatment.
Under these circumstances of treatment evolution in rectal
cancer, patients and physicians have to consider risks and benefits
in choosing the best treatment between the different options now
available. On the other hand, health-care payers increasingly
require evidence of economics in addition to the clinical value,
under the severe pressure to health-care expenditure. However,
there is far less economic evaluation specifically of adjuvant
therapy for rectal cancer than for colon cancer (van den Hout et al,
2002). Only one study, related to cost-effectiveness of adjuvant
therapy for rectal cancer, has been reported (Norum et al, 1997).
Our objective was to confirm the cost-effectiveness of adjuvant
UFT therapy in Japan, extrapolating these results to a time horizon
sufficiently distant to capture all costs and outcomes of relevance.
This study would provide basic information on the cost-
effectiveness of adjuvant therapy for rectal cancer not only in
Japan, but also in other countries indirectly.
MATERIALS AND METHODS
Analytical overview
Economic analysis was conducted retrospectively based on the
Japanese NSAS-CC (Akasu et al, 2006), a multicentre RCT. Patients
with completely resected stage III rectal cancer, who underwent
standardised TME with selective lateral pelvic lymphadenectomy,
were randomly assigned to either oral UFT (400mgm
 2 per day)
for 1 year (n¼139) or surgery alone (n¼135).
As a type of economic analysis (Drummond et al, 2005), a cost-
effective analysis was performed. Incremental costs and effective-
ness of adjuvant UFT therapy compared with surgery alone were
evaluated. According to the effectiveness measure used (i.e., life-
years gained and quality-adjusted life-years (QALYs) gained),
incremental cost-effectiveness ratios (ICERs) were calculated based
on cost per life-year gained and cost per QALY gained,
respectively. In a narrow meaning, the former is termed cost-
effectiveness analysis, whereas the latter is termed cost–utility
analysis.
The payer of National Health Insurance in Japan was adopted as
a perspective of economic analysis (Drummond et al, 2005).
Therefore, for costs, direct medical-care costs (e.g., costs of tests,
drugs, health-care personnel and so on) were examined, whereas
indirect costs (e.g., time costs or production loss among patients
and their families) were not considered. As a time horizon for
evaluation, three levels of time periods (i.e., observational period
(5.6 years), 10-year follow-up and over lifetime) were considered.
As the base case analysis, observational period was used, as this
period incorporated few assumptions for the evaluation.
Effectiveness
The results of the NSAS-CC were used as evidence of effectiveness
in the economic analysis. The clinical results have been presented
in detail elsewhere (Akasu et al, 2006). As is shown in Table 1,
between the UFT therapy group and the surgery alone group, no
statistical differences were observed in age, sex, tumour location or
pathological tumour stage. The incidence of adverse events more
than grade 3 in the UFT therapy group was higher than that in the
surgery alone group. The OS and RFS rates in the UFT therapy
group were higher than those in the surgery alone group (Akasu
et al, 2006).
Using patients’ data, OS and RFS were estimated by the Kaplan–
Meier method, up to 5.6 years from randomisation. Beyond the
observation period of 5.6 years, OS was simulated using the Boag
model (Boag, 1949) combined with the competing risk model
(Gross and Clark, 1975; Maetani et al, 2004) (Figure 1). Commonly
used methods for extrapolating the survival data beyond the
observation include Weibull, Gompertz, exponential, log-normal
and generalised gamma distributions (Lee and Go, 1997). However,
Table 1 Characteristics of subjects and clinical outcomes
UFT
therapy
Surgery
alone
Number of patients 139 135
Age (median) 59 58
Sex (male) 84 83
Location of the tumour
Below the promontrium 43 39
Below the lower edge of the second sacral bone 39 44
Below the rectouterine fossa or rectovesical
fossa
58 53
Pathological tumour stage
a
T1 8 11
T2 21 16
T3 94 91
T4 17 18
Pathological nodal stage
a
N1 89 90
N2 22 22
N3 29 24
Positive lateral pelvic 11 7
Lymph node
Adverse event more than grade 3 24 5
No. of recurrences 32 53
%%
3-year survival (95% CI) 91 (86–97) 81 (73–88)
3-year relapse-free
survival (95% CI) 78 (71–86) 60 (51–69)
CI¼confidence interval; QALYs¼quality-adjusted life-years. The results are
presented according to ITT (intention to treat).
aThe 1997 Tumour Node Metastasis
(TNM) Classification of Malignant Tumours (International Union Against Cancer).
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sthere is no explicit standard for deciding the optimal method. In
this analysis, the Boag model combined with the competing risk
model was used. This model consisted of two components: the
disease-specific survival curve and the disease-independent
survival curve. Although the former was simulated by a log-
logistic model, the latter was simulated by the survival curve of the
general population matched for age and sex of the subjects. Instead
of the log-normal model adopted in the original Boag model, the
log-logistic model was selected in this analysis, according to
Akaike’s Information Criteria (Akaike, 1974).
The mean number of life-years and relapse-free life-years for
patients in each group was estimated as the area under RFS and OS
curves (Willan and Briggs, 2006). In addition, QALYs were
estimated from OS and RFS by weighting each survival by utility
value for each possible health state. Utility values for the health
states were derived from the published study by Ness et al (1999).
This study was identified by a systematic literature search using
MEDLINE and EMBASE and critically appraised. The median
utility (25th, 75th percentile) for stage III after surgery and
metastasis was 0.75 (0.55, 0.85) and 0.20 (0.00, 0.40), respectively.
These utility values were assigned to the health conditions with
and without relapse in this analysis. Although the frequency and
grade of adverse events due to chemotherapy was relatively low,
utility reduction associated with these events was adjusted by the
method adopted by Aballe ´a et al (2007).
Cost
Costs incurred for resources used during trial and subsequent
follow-up were estimated from trial data and their extrapolation.
Resource utilisation during trial and follow-up was derived from
individual patient history data. As observations on many patients
are censored in a clinical trial, subsequent costs are unknown.
To correct for censoring, the cost history method proposed by
Lin et al (Lin et al, 1997; Willan and Briggs, 2006) was applied.
Costs were estimated from the National Health Insurance
perspective using the National Health Insurance reimbursement
list and drug price in 2005 (Institute of Social Insurance, 2005;
Jiho, 2005). Unit costs for chemotherapy (UFT), consultation and
diagnostic tests were low, whereas those of imaging tests for
follow-up were relatively high. Admission fees were considerably
lower than those in the United States.
Resource utilisation for an adverse event treated on an
outpatient basis was estimated for individual patients on standard
management. The treatment was relatively simple and at a low
cost. The cost of a recurrence was estimated according to the type
of recurrence, based on patients’ records during observation. The
majority of recurrence was at distant sites, and chemotherapy
(e.g., FOLFOX4) is recommended as the first-line therapy in the
Japanese guidelines (Japan Society for Cancer of the Colon and
Rectum, 2005). The costs associated with end-of-life care for rectal
cancer were estimated in the same way as for recurrence. Unrelated
health-care costs in the later years of life were not included in this
analysis (Drummond et al, 2005). All costs were converted from
Japanese yen to US dollars based on OECD purchasing power
parity in 2005 ($1¼f128) (OECD, 2007).
Discount
Discounting for the time value of money was applied to both costs
and effectiveness. In the base case analysis, both costs and
effectiveness accruing beyond 1 year were discounted to present
values at a rate of 3%, following the recommendations of the US
Panel on Cost-Effectiveness in Health and Medicine (Gold et al,
1996). However, currently, much debate still surrounds two major
points: the underlying discounting model and the differential
discount rate for health and cost (Gold et al, 1996; National
Institute of Clinical Excellence, 2004; Bos et al, 2005; Brouwer et al,
2005). Therefore, impact of discounting on the results was
examined extensively by sensitivity analysis.
Sensitivity analysis
The uncertainty of the results was explored by stochastic and
qualitative sensitivity analyses of important factors (Glick et al,
2001; Briggs, 2004; Drummond et al, 2005). The impact of
uncertainty on the estimated ICER due to the stochastic nature
of sampled data was analysed by applying a non-parametric
bootstrap resampling technique (i.e., 5000 times) to both costs
and effectiveness. Also, cost-effectiveness acceptability and net
monetary benefit (NMB) analyses (Glick et al, 2001; Briggs, 2004)
were performed. A number of qualitative one-way and two-way
sensitivity analyses were conducted to explore the impact of
alternative parametric assumptions on the results. These included
alternative assumptions concerning time horizon, key cost
parameters, recurrence rate, utility value and discount rate.
Budget impact analysis
To estimate the potential impact of introduction of adjuvant UFT
therapy, instead of surgery alone, on the National Health Insurance
budget in Japan, a budget impact analysis (Trueman et al, 2001)
was performed. The total annual cost to the National Health
Insurance was estimated using the treatment costs for adjuvant
UFT therapy and surgery alone in cost-effective analysis. The time
horizon considered in this analysis was 5.6 years for observation
period of the NSAS-CC. The costs were discounted at 3% of annual
rate. The annual number of the resected stage III rectal cancer in
Japan was estimated multiplying the annual incidence rate of rectal
cancer (Ministry of Health, Labor and Welfare, 2006) by the
proportion of the stage III patients who received initial treatment,
at the National Cancer Centre in Japan (Committee of Cancer
Statistics, 2005).
RESULTS
Effectiveness
The mean LYs and QALYs (3% discount rate) in each group are
shown in Table 2A. For 5.6-year observation, 10-year follow-up
and over lifetime, the mean QALYs for adjuvant UFT therapy were
3.30, 5.43 and 10.68, respectively. Those for surgery alone were
2.81, 4.47 and 8.38, respectively. Adjuvant therapy gained 0.50, 0.96
and 2.28 QALYs (Po0.05). The difference in QALYs was larger
than that in LYs for the 5.6-year observation, but this pattern was
reversed for 10-year follow-up and over lifetime periods.
40 35 30 25 20
Years
15 10 5 0
0
20
40
60
80
100
(
%
) Observation
Surgery alone
(n=135)
UFT
(n=139)
Simulation
Figure 1 Observed survival curve and extrapolated survival estimate.
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The mean costs (no discounting) per person in each group for the
5.6-year observation are shown in Table 3. The mean total cost per
patient was $10026 in the UFT therapy group and $12628 in the
surgery alone group. The costs of recurrence and end-of-life were
the major components in both groups. Although UFT therapy
added over $3000 per patient to the ingredient cost of surgery
alone, this was offset by the reduction of costs in recurrence and
end-of-life of rectal cancer. As is shown in Table 2A, for 5.6-year
observation, 10-year follow-up and over lifetime, adjuvant UFT
therapy reduced costs (3% discount rate) per person by $2457,
$1771 and $1843 compared with surgery alone, respectively. The
difference in the 5.6-year observation was statistically significant
(Po0.05).
Incremental cost-effectiveness ratio
Uracil–tegafur therapy showed dominance (less costly and more
effective). As is shown in Table 2B, ICER for 5.6-year observation,
10-year follow-up and over lifetime was estimated to be  $4969,
 $1815 and  $802 per QALY gained, respectively, using the
bootstrap method (3% discount rate for both effect
and cost). There is little difference between costs per life-year
gained and costs per QALY gained.
Sensitivity analysis
The results of a probabilistic sensitivity analysis are shown in
Figure 2. Figure 2A shows ICER (cost per QALY gained) scatter
plots. More than 95% of the points resided in the southeast
quadrant (i.e., more effective and less costly). The cost-effective-
ness acceptability cure based on 5000 samples of cost-effectiveness
ratio is presented in Figure 2B. Even if additional QALY was valued
as 0, the likelihood of UFT therapy being cost-effective was 98%.
The NMB curve is shown in Figure 2C. The NMB and its
confidence interval (CI) curves did not cross the horizontal axis.
This indicates that UFT therapy was beneficial, even if a decision
maker was not willing to pay anything for the additional QALY.
A number of qualitative sensitivity analyses are shown in Tables
2B and 4. As to time horizon (Table 2B), from 5.6-year observation
to over lifetime, cost-effectiveness ratios were all negative,
indicating more benefits and less costs (i.e., dominance).
The two-way sensitivity analysis of discount rate for both costs
and effect did not show any change in the dominance of UFT
therapy. Incremental cost-effectiveness ratio was lowest ( $5031 per
QALY) at a discount rate of 5% for both costs and effectiveness and
Table 2 Incremental effectiveness and costs of adjuvant UFT therapy (discount rate: 3% for both effectiveness and costs)
Period
UFT
therapy
Surgery
alone
Incremental effectiveness and
costs (95% CI)
(A) Effectiveness and costs
Life years
5.6-year observation 4.89 4.45 0.44 (0.14–0.75)
10-year follow-up 8.06 6.96 1.08 (0.22–1.94)
Over lifetime 16.03 12.93 3.09 (1.29–4.86)
QALYs
5.6-year observation 3.30 2.81 0.50 (0.24–0.76)
10-year follow-up 5.43 4.47 0.96 (0.43–1.47)
Over lifetime 10.68 8.38 2.28 (1.15–3.38)
Costs ($)
5.6-year observation 8742 11199  2457 ( 4751 to  164)
10-year follow-up 10037 11767  1771 ( 4110 to 719)
Over lifetime 10109 11921  1843 ( 4208 to 601)
Incremental cost-effectiveness ratio
Period Cost ($) per LY gained (95% CI) Cost ($) per QALY gained (95% CI)
(B) Cost-effectiveness ratio
5.6-year observation  5559 ( 13254 to  420)  4969 ( 11057 to  364)
10-year follow-up  1573 ( 10188 to 597)  1815 ( 7156 to 634)
Over lifetime  594 ( 2452 to 169)  802 ( 2899 to 233)
CI¼confidence interval; QALYs¼quality-adjusted life-years; UFT¼uracil–tegafur.
Table 3 Mean costs per patient during observation period (no
discounting)
Item UFT therapy Surgery alone
Consultation 125 ($) 56 ($)
Treatment
Drugs 3076 NA
Prescription 66 NA
Tests
Diagnostic tests 346 185
Imaging tests 1068 1098
Side effects 2 1
Recurrence 3212 5061
End of life 2131 6226
Total costs 10026 12628
NA¼not applicable; UFT¼uracil–tegafur.
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effectiveness ratio increased with increase of discount rate of cost,
whereas ICER decreased with increase of discount rate of effect.
The results of one-way sensitivity analyses are shown in Table 4.
Variations in recurrence rate, utility value, QALYs and the
acquisition cost of UFT did not influence the dominance of UFT
therapy. On the other hand, with variations of total cost, ICERs
varied from  $9695 to $334 per QALY gained. This upper limit of
ICER was positive, but at a very low level.
Budget impact
The annual incidence rate of rectal cancer was 3.23 10
4 and the
proportion of the stage III patients was 32.5%. Then, the annual
number (95% CI) of the resected stage III rectal cancer was
estimated to be 1.05 10
4 (0.91–1.20). The cost reduction per
patient was $2603. Therefore, a budget impact converting from
surgery alone to adjuvant UFT therapy would reduce current
medical expenditure by $27.3 million (95% CI, $23.7 million, $31.2
million) in the first 5.6 years after its adoption.
DISCUSSION
From the perspective of the National Health Insurance in Japan,
this cost-effectiveness analysis of UFT adjuvant therapy for stage
III rectal cancer would save health-care costs and improve health
outcomes, compared with surgery alone (Table 2). Uracil–tegafur
therapy has proved dominant (less costly and more effective). The
cost–utility ratio of UFT can be ranked near the top of league table
of cost–utility in oncology (Earle et al, 2000). The cost savings on
the National Health Insurance budget during the observational
period would be approximately $27.3 million.
There has been little evidence on economic evaluation of
adjuvant therapy for rectal cancer (van den Hout et al, 2002). Only
one cost-effective analysis of adjuvant therapy for Dukes’ B and C
colorectal cancer (Norum et al, 1997), of which about two-third
consisted of colon cancer, has shown that cost per QALY gained of
5-FU/levamisole was between d4800 and d16,800, compared with
surgery alone. This result is highly cost-effective compared with
the recent threshold (Jonsson, 2004) for cost-effectiveness.
However, cost-effectiveness ratio in our study is much better than
that, even though these results are not directly comparable with
each other. In the area of rectal cancer, economic evaluations on
the standard adjuvant therapy (i.v. 5-FU/radiation) comparing
control (i.e., surgery alone), as well as head-to-head evaluation
comparing newly emerging with the standard therapy, are urgently
needed for health-care decision making. Our study provides basic
information in comparing cost-effectiveness of adjuvant therapies
for rectal cancer.
To estimate stochastic uncertainty of ICER due to sampling bias
in this study, probabilistic sensitivity analyses (Glick et al, 2001;
Briggs, 2004; Drummond et al, 2005) were performed (Table 2,
Figure 2). Cost-effectiveness scatter plots showed that CIs of ICER
located in the southeast quadrant (more effective and less costly)
on the cost-effectiveness plane. Cost-effectiveness acceptability
and NMB curves give more information than simple intervals or
plots of ICERs mentioned above. Even if a decision maker was
unwilling to invest anything at the maximum to achieve additional
QALY, the likelihood of UFT therapy being acceptable as cost-
effective was 98% (Figure 2B). At the same condition, the NMB
curve showed that UFT therapy was beneficial ($2450 per person)
(Figure 2C). These results show that the dominant cost-effective-
ness of UFT adjuvant therapy is robust. This dominance was
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Figure 2 Stochastic sensitivity analyses. (A) Incremental cost-effective-
ness scatter plot of UFT therapy. (B) Cost-effectiveness acceptability curve
of adjuvant UFT therapy. (C) Net monetary benefit curve of adjuvant UFT
therapy with 95% confidence intervals.
Table 4 One-way sensitivity analysis of important factors
Factor
Cost-effectiveness ratio
($ per QALY gained)
Base case analysis  4969
Recurrence rate (95% CI)  5304 to  4679
Utility (25th, 75th percentile)
Non-recurrence  7063 to  4328
Recurrence  5593 to  4471
QALY (95% CI)  10434 to  3244
UFT cost (95% CI)  7506 to  2432
Total cost (95% CI)  9695 to 334
CI¼confidence interval; QALY¼quality-adjusted life-year; UFT¼uracil–tegafur.
Discount rate: 3% for both cost and effectiveness; period: observation.
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sshown more sensitive to costs than effectiveness by the scatter plot
of ICERs (Figure 2A) and broad one-way sensitivity analysis on
both QALY gained and total costs (Table 4).
The time horizon is an important issue to sufficiently capture
relevant costs and health outcomes of UFT adjuvant therapy. The
observation period of the NSAS-CC, 5.6 years, was limited.
Although most costs were incurred mainly in the observational
period, life-years gained would continue after it. In this study, a
simulation model was used to extrapolate its results. There is a
variety of ways for simulation (Lee and Go, 1997), but no uniform
methodology is available. In the analysis, we used the Boag model
combined with the competing risk model (Maetani et al, 2004). In
a sensitivity analysis, ICER of the observational period (the base
case analysis) was compared with that in the extrapolated periods
(i.e., 10-year follow-up and over lifetime). These ICERs were
dominant (more effective and less costly) in spite of relative
differences in their values.
The key drivers of the dominant cost-effectiveness results of
UFT are mainly the savings achieved by reduction of costs related
to recurrence and death, which offset the acquisition cost of UFT.
After a 4-year follow-up, any recurrence has not been observed in
this study. In one-way sensitivity analysis (Table 4), varying
recurrence rates between 95% CIs did not have any substantial
impact on dominant cost-effectiveness. The other cost driver was
the acquisition costs of UFT. Variation in the price of UFT and its
standard regimen would be unlikely. Varying acquisition costs of
UFT did not have any impact of dominance (Table 4).
Cost-effectiveness analysis using QALYs offers the opportunity
to consider both quantity and quality of survival. However, no
substantial difference in ICERs was observed between cost per
LY gained and QALY gained (Table 2). In addition, the sensitivity
analysis on range of utility values for recurrence and non-
recurrence revealed no major change in dominant cost-effective-
ness (Table 4). In a sizable fraction of cost-effectiveness analysis,
utility weighting was indicated not to substantially alter the
estimated cost-effectiveness of an intervention (Chapman et al,
2004). It is thus suggested that sensitivity analyses using ad hoc
adjustment or weight from the literature may be sufficient. Our
results support this conclusion.
The impact of discounting for the time value of money on the
results was examined extensively by two-way sensitivity analyses.
Although ICERs were more sensitive to cost discounting than
effectiveness discounting, there was no substantial change in
dominant cost-effectiveness. The main reason is likely to be that
major costs were incurred during the early phase of follow-up and
improved survival was realised simultaneously.
There are several limitations in the analysis that should be
c o m m e n t e do n ,a n dt h er e s u l t ss h o u l db et r e a t e dw i t hc a u t i o n .F i r s t ,
the analysis was based on a small RCT with relatively short-term
follow-up (Akasu et al,2 0 0 6 ) .T h e r e f o r e ,e x t e n s i v es e n s i t i v i t ya n a l y s e s
were performed to examine this uncertainty. However, large-scale
RCTs are crucial to resolving this issue. Second, the UFT adjuvant
therapy was the only chemotherapy that showed improvement in OS
and DFS compared with surgery alone in Japan. As there is no RCT
comparing the standard adjuvant therapy (e.g., 5-FU/radiation) with
surgery alone or UFT, it is impossible to directly or indirectly compare
these therapies. In future, head-to-head evaluations comparing new
emerging therapies (e.g., capecitabine and oxaliplatin) will need to be
carried out. Third, the perspective of this analysis is that of a payer for
health care, rather than a society. From a societal perspective, the
range of costs is broader and includes time costs and travel costs
associated with treatment and loss of production due to earlier death.
As UFT adjuvant therapy increased OS and decreased recurrence,
their cost reduction in both indirect costs and direct costs will offset
the costs corresponding to a treatment period.
The issue of generalisability of this study to other countries
should be carefully examined, as the UFT adjuvant therapy is the
standard in Japan. However, as mentioned in the introduction, in
contrast to colon cancer, there is no firm evidence for effectiveness
of the western standard therapy (e.g., FU/LV) in rectal cancer.
Moreover, given the high treatment costs, substantial toxicity
and relatively limited efficacy of the fast-changing chemo- and
immunotherapeutic combinations for colorectal cancer, examina-
tion of cost-effectiveness studies should be conducted on a routine
basis along with determination of clinical benefits (Jansman et al,
2007). Uracil–tegafur has been approved and utilised in 31
countries from Europe and Canada to Asia, excluding the United
States. Recently, several studies of combination therapies of
UFT/LV in metastatic colorectal cancer have shown efficacy
(Bennouna et al, 2006; Bajetta et al, 2007). Therefore, the results
of this study indicating effectiveness and cost-effectiveness of
UFT adjuvant therapy in rectal cancer may be useful as a reference
case for the direct or indirect future examination internationally.
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